Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA
These results from US clinical practice suggest greater reductions in OCS and NSIST concomitant therapy for patients treated with ravulizumab or eculizumab compared with efgartigimod.
Authors
- Guido Sabatella
- Nicholas J. Silvestri (ORCID: https://orcid.org/0000-0001-7931-0930)
- Francesco Saccà (ORCID: https://orcid.org/0000-0002-1323-6317)
- Karen W L Yee (ORCID: https://orcid.org/0000-0002-2572-9952)
- Justin Lee (ORCID: https://orcid.org/0000-0003-2444-0169)
Institutions
- Federico II University Hospital (IT)
- Alexion Pharmaceuticals (United States) (US)
- AstraZeneca (United States) (US)
- Jacobs (United States) (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1007/s40120-025-00873-0
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00